Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADTPSMA2: PSMA-flare after Degarelix in metastatic prostate cancer
NCT03876912Unknown
- Sponsor
- Turku University Hospital
- Start
- Mar 2019
- Primary completion
- Sep 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of degarelix in Metastatic Prostate Cancer (mPC), sponsored by Turku University Hospital. Primary endpoint: PSMA-flare after ADT. Status: unknown.
02
Drugs
degarelix
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT03876912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03876912.